Literature DB >> 6155396

Regulation of experimental allergic encephalomyelitis. II. Appearance of suppressor cells during the remission phase of the disease.

A M Welch, J H Holda, R H Swanborg.   

Abstract

Lewis rats are susceptible to experimental autoimmune encephalomyelitis (EAE). Most rats recover from paralysis and are subsequently resistant to the disease. In an adoptive transfer system, we found that lymph node cells (LNC) from rats that had recovered from EAE protect syngeneic recipients from the disease when the latter are challenged with encephalitogenic myelin basic protein and adjuvant after receiving donor cells. Suppression is antigen-specific and requires viable LNC. In contrast to the suppressor cells we previously studied in tolerized rats, which were nonadherent T lymphocytes, the suppressor cells found in rats that have recovered from EAE adhere to glass wool. However, they are not retained on Sephadex G-10 columns to which macrophages adhere. Suppressor activity is enriched in the nylon wool-adherent LNC population (which consists of approximately 80% Ig+ cells). Our findings suggest that activation of adherent suppressor cells may be implicated in recovery from EAE. These may be adherent T cells, or B cells that produce anti-BP blocking antibodies.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6155396

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  In vivo priming of IL-17(+) uveitogenic T cells is enhanced by Toll ligand receptor (TLR)2 and TLR4 agonists via γδ T cell activation.

Authors:  Aijun Zuo; Dongchun Liang; Hui Shao; Willi K Born; Henry J Kaplan; Deming Sun
Journal:  Mol Immunol       Date:  2012-02-01       Impact factor: 4.407

2.  Phenotypic and functional characterization of T cells from patients with myasthenia gravis.

Authors:  F Mokhtarian; M Pino; W Ofosu-Appiah; D Grob
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

Review 3.  Characterization and distribution of lymphocyte subpopulations in multiple sclerosis plaques versus autoimmune demyelinating lesions.

Authors:  U Traugott
Journal:  Springer Semin Immunopathol       Date:  1985

4.  The role of serum factors in the suppression of experimental allergic encephalomyelitis: evidence for immunoregulation by antibody to the encephalitogenic peptide.

Authors:  I A MacPhee; M J Day; D W Mason
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

5.  Autoimmune effector cells. VII. Cells isolated from thymus and spinal cord of rats with experimental allergic encephalomyelitis transfer disease.

Authors:  N S Hayosh; R H Swanborg
Journal:  Am J Pathol       Date:  1986-02       Impact factor: 4.307

6.  Myelin basic protein-reactive T cells persist in an inactive state in the bone marrow of Lewis rats that have recovered from autoimmune encephalomyelitis.

Authors:  Taba Kheradmand; Norbert A Wolf; Robert H Swanborg
Journal:  J Neuroimmunol       Date:  2009-02-10       Impact factor: 3.478

7.  Attempts to suppress experimental allergic neuritis in the rat by pretreatment with antigen.

Authors:  J V Brosnan; R I Craggs; R H King; P K Thomas
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

8.  Preventive and therapeutic effects of cyclosporin and valine2-dihydro-cyclosporin in chronic relapsing experimental allergic encephalomyelitis in the Lewis rat.

Authors:  C Feurer; L H Chow; J F Borel
Journal:  Immunology       Date:  1988-02       Impact factor: 7.397

9.  Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids.

Authors:  I A MacPhee; F A Antoni; D W Mason
Journal:  J Exp Med       Date:  1989-02-01       Impact factor: 14.307

10.  Genetic resistance to the induction of experimental allergic encephalomyelitis in Lewis rats. I. Genetic analysis of an apparent mutant strain with phenotypic resistance to experimental allergic encephalomyelitis.

Authors:  F J Waxman; L E Perryman; D J Hinrichs; J E Coe
Journal:  J Exp Med       Date:  1981-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.